Bushu and Takeda Announce Transformational Pharmaceutical Sciences Partnership

Bushu and Takeda Announce Transformational Pharmaceutical Sciences Partnership

February 28, 2017

- A Part of Takeda's Pharmaceutical Sciences Capability Transfers to Bushu
Partnership Enables More Efficient Operations for the Development and Manufacturing 
of Clinical Trial Materials

Bushu Pharmaceuticals Limited and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that the companies have entered into a new partnership agreement under which Takeda will transfer a part of its Pharmaceutical Sciences/CMC* business to Bushu. Bushu, as a strategic partner of Takeda, will deliver on process chemistry, formulation and analytical development, as well as development, manufacturing and associated work of clinical trial materials.

*CMC stands for chemistry, manufacturing and controls, which is the research and development activities including the design of API or formulation and product quality, and the development of manufacture processes to put new drug candidates discovered through research onto the market.

“This strategic partnership is a critical part of Takeda’s R&D transformation which enables a more agile and flexible approach for the drug development and manufacturing by focusing resources and activities to better meet patient needs,” said Jim Morley, Ph.D., Head of Pharmaceutical Sciencesat Takeda. “Bushu has an excellent reputation in Japan for providing high quality contract manufacturing solutions. Within this unique collaboration, we believe Bushu will be an ideal partner for Takeda as we focus, deliver, and advance our current and future pipeline.”

“This partnership enable us to expand our scope of business services, transforming our business from a traditional CMO model which serves in the commercial manufacturing, drug product manufacturing and packaging for clinical trial materials, to a truly one-stop service provider which covers the full range of drug development,” said Jun Yokohama, Representative Director, President and CEO, Bushu. “As a strategic partner that supports Takeda R&D, we will focus on enhancing technical capability, building robust business foundation to meet requirements from various customers. This partnership will be our important cornerstone of globalization.”

This partnership is a complementary relationship between Takeda and Bushu that aims to improve Takeda’s operating efficiencies and create a more agile organization while enabling Bushu to broaden the scope of its current service offerings and its global reach by leveraging the two companies’ combined operational expertise and a wide range of manufacturing capabilities.

In the second quarter of FY2017, Bushu will acquire a wholly owned subsidiary of Takeda which will be established in the first quarter of FY2017. This subsidiary will encompass a part of Takeda's Pharmaceutical Sciences business including approximately 200 Takeda employees and a significant part of its R&D manufacturing facilities in Juso (Yodogawa-ku, Osaka city), via an absorption-type company split.

About Bushu

Bushu Pharmaceuticals Ltd. was established in August 1998 as an independent pharmaceutical contract manufacturer and today is the leading pharmaceutical CMO in the Japan market. Bushu is engaged in the pharmaceutical contract manufacturing and packaging of clinical trials and commercial products in accordance with latest GMP standards. Through the utilization of know-how and latest industry information, Bushu prides itself in being able to offer added value solutions to customers. The company operates two manufacturing facilities located in Kawagoe and Misato in Saitama prefecture. For more information, refer to our website: http://www.bushu-seiyaku.co.jp/en/index.html

About Takeda

Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases as well as late-stage candidates for vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology, central nervous system and gastroenterology, as well as its presence in emerging markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries.

For more information, visit http://www.takeda.com/news

Media Contacts:

For Bushu:
Hirofumi Takeuchi
[email protected]
+81 (0)49-233-4651

For Takeda:
Kazumi Kobayashi
[email protected]
+81 (0) 3-3278-2095


# # #